Projektbeschreibung
Neue therapeutische Zielstrukturen bei der Behandlung seltener Krankheiten und Krebs
Der PI3K-Signalweg (Phosphoinositid-3-Kinase) ist ein wichtiger Regulator von Zellwachstum, Stoffwechselprozessen und Lebensfunktionen. Die Phosphatase PTEN (Phosphatase and Tensin Homolog) ist ein negativer Regulator dieses Signalwegs und wirkt als Tumorsuppressor. Das EU-finanzierte Projekt PIPgen baut auf Forschungen zur Beteiligung von PI3K/PTEN an der Tumorbildung auf und untersucht deren Einfluss auf die Entstehung monogener seltener Krankheiten wie Großwuchssyndrom, primäre Immunschwächen und geistige Behinderung. Der Beitrag von PI3K zu seltenen Krankheiten lässt wiederum Rückschlüsse auf Krebserkrankungen zu. Das neue Grundlagenwissen könnte die Basis für neue Therapien gegen viele seltene Krankheiten schaffen, die europaweit Millionen von Menschen betreffen.
Ziel
There are more than 7000 rare diseases, affecting approximately 30 million European Union citizens. Eighty percent of rare diseases have monogenic origin and are often chronic or life-threatening. Several of these genetic mutations are also implicated in cancer, a disease of epidemic proportions (>14 million new cases/year worldwide). Genetic alterations in the PI3K/PTEN pathway are common events in both monogenic rare diseases and in cancer. Despite the molecular commonalities, these two pathologies have predominantly been investigated as independent entities. We aim to take advantage of the knowledge that has been generated regarding the role of PI3K in cancer to better understand the recently-discovered PI3K-related rare diseases (overgrowth syndromes, primary immunodeficiencies and cognitive deficiencies). Conversely, discoveries emanating from PI3K-related rare diseases will impact in the understanding of cancer. Ultimately, this cross-fertilization will impact on the clinical strategies to treat both rare diseases and cancer. Our network, under the acronym of PIPgen, aims to (1) produce the next generation of scientists that can navigate with ease between academic, industrial and clinical sectors and have the scientific and softs skills to convert research findings into commercialization and clinical applications, and (2) generate innovative knowledge that can be translated to the diagnosis and treatment of both rare diseases and cancer. This network provides a pan-European interdisciplinary and intersectorial training program of excellence bringing young researchers together with world leading academics, clinicians, entrepreneurs with experience from the pharma industry, corporate research as well as with dissemination and outreach activities. PIPgen has been conceived to make a real therapeutic impact both in rare diseases and cancer, based on basic bioscience.
Wissenschaftliches Gebiet
Schlüsselbegriffe
Programm/Programme
Thema/Themen
Aufforderung zur Vorschlagseinreichung
Andere Projekte für diesen Aufruf anzeigenFinanzierungsplan
MSCA-ITN - Marie Skłodowska-Curie Innovative Training Networks (ITN)Koordinator
08916 Badalona
Spanien